TriSalus Life Sciences (TLSI) Notes Payables (2021 - 2023)

TriSalus Life Sciences has reported Notes Payables for 3 years, with the latest figure at $1.6 million in Q2 2023.

• For the quarter ending Q2 2023, Notes Payables rose 66.65% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2023 stood at $1.6 million (up 66.65% YoY), and the FY2022 full-year result was $944000.0, up 73.53% from the prior year.
• Notes Payables for Q2 2023 stood at $1.6 million, up from $1.4 million in the prior quarter.
• The five-year high for Notes Payables was $1.6 million in Q2 2023, with the low at $544000.0 in Q4 2021.
• Historically, Notes Payables has averaged $1.0 million across 3 years, with a median of $944000.0 in 2022.
• Annual changes were most pronounced in 2022 — Notes Payables soared 73.53% — and 2023, when it surged 66.65%.
• TriSalus Life Sciences' Notes Payables stood at $544000.0 in 2021, then soared by 73.53% to $944000.0 in 2022, then surged by 66.65% to $1.6 million in 2023.
• The last three Notes Payables figures came in at $1.6 million (Q2 2023), $1.4 million (Q1 2023), and $944000.0 (Q4 2022), per Business Quant data.